Gsto2 and Ptger3 levels were altered in PD and LID rats (Figure 4A and Supplementary Figure 2)—i.e., they were decreased in PD rats after 6-OHDA administration and further reduced in LID rats, but these trends were reversed in NLID rats after L-DOPA administration (Figure 4A). This evidence concerns the gene GSTO2 and Parkinson disease.